Correction
First published: 11 April 2014
The authors would like to draw the reader's attention to an error in the following article:
Yuichi Ando, Megumi Inada-Inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt and Toshihiko Doi
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
Cancer Sci 2014; 105: 347–353. This article has been published on Early View on February 13, 2014.
On page 352, one of the doctors’ names in the Acknowledgement section has been incorrectly presented.
“Dr Akifumi Kato” should be corrected to:
“Dr Terufumi Kato”
The authors apologize for this error and any confusion it may have caused.
